Dung T Le
Sidney Kimmel Comprehensive Cancer Center · Baltimore, United States
Is this your team? Claim it
Research view
Switch to patient viewPancreatic cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target or a country to narrow the list.
- All targets
- KRAS 67
- PD-1 39
- TP53 4
- mTOR 0
- PI3K 0
- STAT3 0
- PD-L1 20
- CLDN18 21
- EGFR 11
- RAS 17
- BRCA2 8
- AKT 0
- BRCA1 10
- ERK 0
- MAPK 1
- PARP 9
- STING 0
- HER2 13
- MYC 0
- YAP 0
- MEK 5
- PALB2 9
- CTLA-4 9
- VEGF 3
- AMPK 0
- ATM 3
- CD40 2
- CXCR4 0
- HIF-1 0
- JNK 0
- NRF2 0
- CDKN2A 3
- GLP-1 2
- NRAS 5
- PRMT5 6
- IL-6 0
- PPAR 0
- PTEN 0
- BCL-2 0
- FAK 1
- IL-15 1
- JAK 0
- TROP2 3
- BRAF 2
- MET 2
- B7-H3 2
- CDK4/6 0
- FGFR 1
- HSP90 0
- CTNNB1 0
- HDAC 0
- KEAP1 1
- CD47 0
- METTL3 0
- MUC1 3
- AXL 1
- CCR5 0
- HER3 1
- NTRK 1
- RET 0
Ryan C Fields
Washington University in St. Louis · St Louis, United States
Is this your team? Claim it
Latest publication · Cancer Immunol Res, Feb 2026Intratumoral Three-Cell-Type Clusters Are a Conserved Feature of Endogenous Antitumor Immunity.
2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
European Commission (Horizon Europe) · HORIZON-ERC
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies (GlycoIMPACT)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN
European Commission (Horizon Europe) · HORIZON-ERC
Evoking anti-tumor immunity in pancreatic cancer (Evoke-PDAC)
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE
5 of 58 running projects, newest first. Listed amounts together: €177.8m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
No trial in this view states that it shares participant data.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 50
- Organoids 47
- Mendelian Randomization Analysis 29
- CRISPR-Cas Systems 16
- Gene Expression Profiling 123
- Sequence Analysis, RNA 11
- Whole Genome Sequencing 3
- Exome Sequencing 10
- Proteomics 55
- Metabolomics 34
- Mass Spectrometry 10
- Flow Cytometry 32
- Immunohistochemistry 70
- Liquid Biopsy 30
- Circulating Tumor DNA 29
- Xenograft Model Antitumor Assays 300
- Positron-Emission Tomography 30
- Magnetic Resonance Imaging 117
- Machine Learning 58
- Deep Learning 55
- Cohort Studies 108
- Genome-Wide Association Study 24
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.